- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.09. | Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement | 522 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / August 31, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F)... ► Artikel lesen | |
| 29.08. | Lobe Sciences Ltd (2): Lobe Sciences increases private placement to $2.16M | 2 | Stockwatch | ||
| 29.08. | Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement | 558 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 28, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE)... ► Artikel lesen | |
| 28.08. | Lobe Sciences Ltd (2): Lobe Sciences appoints Kideckel as CFO | 1 | Stockwatch | ||
| 28.08. | Lobe Sciences Ltd.: Lobe Sciences Expands Leadership Team with New CFO Appointment | 334 | ACCESS Newswire | Dr. David Kideckel, PhD, MBA, joins as Chief Financial Officer, bringing nearly two decades of life sciences, capital markets and corporate advisory experienceCurrent CFO, Mirza Rahimani, transitions... ► Artikel lesen | |
| 20.08. | Lobe Sciences Ltd (2): Lobe Sciences closes $2.1-million private placement | 1 | Stockwatch | ||
| 20.08. | Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement | 255 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE)... ► Artikel lesen | |
| 19.08. | Lobe Sciences reports Q3 results | 1 | Seeking Alpha | ||
| LOBE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 18.08. | Lobe Sciences Ltd.: Lobe Sciences Reports Third Quarter 2026 Financial Results | 275 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / August 18, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company advancing therapeutic... ► Artikel lesen | |
| 13.08. | Lobe Sciences Ltd (2): Lobe Sciences arranges $2.1-million private placement | 1 | Stockwatch | ||
| 12.08. | Lobe Sciences to raise C$2.1M in private placement | 3 | Seeking Alpha | ||
| 12.08. | Lobe Sciences Ltd. Announces Non-Brokered Private Placement | 567 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 12, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F) ("Lobe"... ► Artikel lesen | |
| 05.08. | Lobe Sciences Ltd.: Lobe Sciences Announces Results of Annual General and Special Meeting of Shareholders | 308 | ACCESS Newswire | Shareholders Approve All Matters Presented at Meeting, Including New Long-Term Incentive Plan and Amendment to Constating Documents VANCOUVER, BC / ACCESS Newswire / August 5, 2026 / Lobe Sciences Ltd.... ► Artikel lesen | |
| 07.07. | Lobe Sciences Ltd (2): Lobe Sciences schedules AGSM for July 30 | 1 | Stockwatch | ||
| 07.07. | Lobe Sciences Ltd.: Lobe Sciences Files Management Information Circular for Annual General and Special Meeting on July 30, 2026 | 465 | ACCESS Newswire | The Company's Annual General and Special Meeting will be held on Thursday, July 30, 2026, at 11:00 a.m. (Vancouver time), at 15th Floor, 1111 West Hastings Street, Vancouver, British Columbia, with... ► Artikel lesen | |
| 09.06. | Lobe Sciences Ltd (2): Lobe Sciences settles $1.37M in mgmt, director fees | 3 | Stockwatch | ||
| 09.06. | Lobe Sciences Ltd.: Lobe Sciences Directors and Management Increase Equity Ownership Through Settlement of Accrued Fees by the Issuance of Common Shares | 332 | ACCESS Newswire | Directors and management elected to receive restricted equity in place of accrued fees payable, thereby increasing ownership and further aligning with shareholdersThe Canadian Securities Exchange has... ► Artikel lesen | |
| 02.06. | Lobe Sciences Ltd.: Lobe Sciences Announces Proposed Shares for Debt Transaction | 442 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / June 1, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates... ► Artikel lesen | |
| 07.05. | Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York | 580 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. ("Lobe", or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential... ► Artikel lesen | |
| 06.05. | Lobe Sciences Ltd.: Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress | 326 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates... ► Artikel lesen |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONXT SOLUTIONS | 0,214 | -2,73 % | Biotech: Jetzt auf den Rebound setzen! Übernahmegefahr für Evotec und BioNxt, Bayer und BioNTech mit vollen Kassen | Der Biotech-Sektor steht nach einer langen Durststrecke vor einer spektakulären Trendwende, die mutigen Anlegern massive Renditechancen bietet. Denn die Kurse vieler innovativer Hoffnungsträger notieren... ► Artikel lesen | |
| ATAIBECKLEY | 6,250 | -0,79 % | Emyria vor Meilenstein: Erste Sydney-Klinik ist startbereit für Psychdelika-Patienten | ||
| SOL GLOBAL INVESTMENTS | 0,026 | -100,00 % | SOL Global Investments Corp.: SOL Global Announces Resignation of Pad Gopal, Chief Financial Officer and Interim Chief Executive Officer | Toronto, Ontario--(Newsfile Corp. - June 25, 2026) - SOL Global Investments Corp. (CSE: SOL) (OTC Pink: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company"), announces that Mr. Pad Gopal has provided... ► Artikel lesen | |
| CYBIN | 11,180 | +5,27 % | CYBIN INC. - 6-K, Report of foreign issuer | ||
| ENTHEON BIOMEDICAL CORP | 0,034 | 0,00 % | Entheon Biomedical Corp.: Entheon Announces Change of Directors | Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces the appointment of Adam Emes... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,008 | +6,67 % | Revive Therapeutics Ltd.: Revive Therapeutics Announces Proposed Shares for Debt Settlement | TORONTO, ON / ACCESS Newswire / August 19, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development... ► Artikel lesen | |
| RAPID DOSE THERAPEUTICS | - | - | Rapid Dose Therapeutics Corp.: Rapid Dose Therapeutics and Aavishkar Granted Monolayer QuickStrip Nicotine Patent, Advancing RDT's Global Commercialization Strategy | Burlington, Ontario--(Newsfile Corp. - August 20, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company specializing in innovative... ► Artikel lesen | |
| QIAGEN | 36,620 | +0,41 % | QIAGEN N.V. - 6-K, Report of foreign issuer | ||
| SUMMIT THERAPEUTICS | 17,470 | +1,10 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| TANGO THERAPEUTICS | 23,760 | +4,67 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| DYNE THERAPEUTICS | 19,550 | -3,74 % | Aktien New York Ausblick: Dow schwächelt weiter - Nasdaq stabil erwartet | NEW YORK (dpa-AFX) - Die US-Börsen steuern nach dem verlängerten Wochenende am Dienstag auf eine durchwachsene Eröffnung zu. Auf die Stimmung drückten die weiter steigenden Ölpreise, die der Angst... ► Artikel lesen | |
| TYRA BIOSCIENCES | 21,445 | -19,77 % | Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib | TYRA's mission is to make dabogratinib the clear first-line treatment choice for patients with LG IR NMIBC
Favorable safety and tolerability results support chronic... ► Artikel lesen | |
| BIOAFFINITY TECHNOLOGIES | 10,380 | +16,24 % | Morning Market Movers: Focus Universal, CEA Industries, bioAffinity Technologies, Dyne Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:55 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 118,09 | +3,28 % | Inhibrx Biosciences, Inc.: Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study | First OX40 agonist to demonstrate clinical benefit in a randomized study
INBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients remain progression... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 24,030 | -1,48 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen |
Das Unternehmen LOBE SCIENCES LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,043 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOBE SCIENCES LTD finden Sie auf Wallstreet Online.